Table 1.
Current status of cell therapy clinical trials of traumatic brain injury (TBI)
| NCT number | Title | Status | Interventions | Phases | Enrollment |
|---|---|---|---|---|---|
| NCT04063215 | A clinical trial to determine the safety and efficacy of hope biosciences autologous mesenchymal stem cell therapy for the treatment of traumatic brain injury and hypoxic‐ischemic encephalopathy | Not yet recruiting | Drug: HB‐adMSC | Phase 1 Phase 2 | 24 |
| NCT02525432 | Autologous stem cell study for adult TBI (Phase 2b) | Enrolling by invitation | Biological: Placebo Infusion Biological: Autologous BMMNC Infusion | Phase 2 | 55 |
| NCT01575470 | Treatment of severe adult traumatic brain injury using bone marrow mononuclear cells | Completed | Biological: autologous bone marrow mononuclear cells | Phase 1|Phase 2 | 25 |
| NCT02416492 | A study of modified stem cells in TBI | Completed | Biological: SB623 cells Procedure: Sham Control | Phase 2 | 61 |
| NCT01851083 | pediatric autologous bone marrow mononuclear cells for severe traumatic brain injury | Active, not recruiting | Biological: autologous bone marrow mononuclear cells|Other: Placebo Infusion | Phase 1|Phase 2 | 47 |
| NCT02959294 | Use of adipose‐derived stem/stromal cells in concussion and traumatic brain injuries | Enrolling by invitation | Procedure: Microcannula Harvest Adipose|Device: Centricyte 1000|Procedure: Sterile Normal Saline IV deployment AD‐cSVF | Phase 1|Phase 2 | 200 |